Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen-Reference-Cited by-同舟云学术

Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen

Published:2018-06-06 Issue: Volume: Page:
ISSN:1021-335X
Container-title:Oncology Reports
language:
Short-container-title:Oncol Rep

Author:

Cortellini Alessio¹^ORCID,Cannita Katia²^ORCID,Parisi Alessandro²,Venditti Olga²,Lanfiuti Baldi Paola²,De Berardis Berardo³,Vicentini Roberto⁴,Vicentini Vincenzo⁵,Verna Lucilla⁶^ORCID,Porzio Giampiero²^ORCID,Ficorella Corrado²^ORCID

Affiliation:

1. Medical Oncology Unit, San Salvatore Hospital, University of L'Aquila, L'Aquila�I‑67100, Italy

2. Medical Oncology Unit, San Salvatore Hospital, University of L'Aquila, L'Aquila I‑67100, Italy

3. Department of General Surgery, ‘Villa Anna’ Clinic, San Benedetto del Tronto 63074, Italy

4. Department of Hepatobiliary and Pancreatic and Emergency Surgery, San Salvatore Hospital, L'Aquila�I‑67100, Italy

5. Department of Hepatobiliary and Pancreatic and Emergency Surgery, San Salvatore Hospital, L'Aquila I‑67100, Italy

6. Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila�I‑67100, Italy

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology,General Medicine

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis;Frontiers in Oncology;2022-08-12

2. Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future;Cancers;2020-09-11

3. Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study;Journal of Cancer Research and Clinical Oncology;2019-07-06